The Effect of Direct Antiviral Therapy on Hepatitis c Virus-related Thrombocytopenia
Not Applicable
- Conditions
- Hepatitis C
- Interventions
- Drug: sofosbuvir daclatasvirDrug: Ledipasvir/sofosbuvir
- Registration Number
- NCT03169348
- Lead Sponsor
- Assiut University
- Brief Summary
Autoimmune thrombocytopenic purpura is an immunological disorder characterized by increased platelet destruction due to presence of anti-platelet antibodies. Hepatitis C virus infection, which is one of the most common chronic viral infections worldwide, may cause secondary chronic immune thrombocytopenic purpura. It seemed to play a pathogenic role in autoimmune thrombocytopenic purpura. Moreover, the successful response (negative hepatitis C virus - ribonucleic acid) to tapered steroids and antiviral therapy was useful to revert thrombocytopenia
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
- Hepatitis C virus infection and thrombocytopenia before treatment
Read More
Exclusion Criteria
- Infection Hepatitis B virus
- Hypersplenism
- Diseases affecting Bone marrow
- Major clotting factors abnormalities eg. Disseminated intravascular coagulopathy, severe Prothrombin deficiency
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description study group Ledipasvir/sofosbuvir Hepatitis- C virus with thrombocytopenia study group sofosbuvir daclatasvir Hepatitis- C virus with thrombocytopenia
- Primary Outcome Measures
Name Time Method the mean difference on the platelet count 6 month
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Assiut University
🇪🇬Assiut, Egypt